NCT05186974

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 193 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Sacituzumab Govitecan-hziy (SG)	Administered intravenously
DRUG	Pembrolizumab	Administered intravenously
DRUG	Carboplatin	Administered intravenously
DRUG	Cisplatin	Administered intravenously

Timeline

• Start date: 2022-05-30
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2022-01-11
• Last updated: 2026-02-11

Locations

101 sites across 12 countries: United States, Australia, Canada, France, Germany, Hong Kong, Italy, Malaysia, South Korea, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study